Why isn't Colostat being sold into European markets and NZ?, page-39

The closest mention of quantity I could find, Stezza, is in the Q2FY21 quarterly released on 28 Jan 21:

Transfer of prototype test-kit to high volume manufacturer-ACHIEVED

Put into context of Rhythm regularly talking about the millions of people that should be checked each year I presume the reference to Biotem being a "high volume manufacturer" means that they have the capacity to produce enough kits to accommodate those sorts of numbers. As in millions produced each year as against hundreds or thousands.

That Rhythm has now appointed a second manufacturer suggests that either Biotem has fessed up that they are not up to it after all OR that Rhythm is expecting two "high volume" orders to come through in the same period of time. Total guess work by me of course.

As it happens, I am killing a bit of time by reviewing the stocks I follow after what has turned out to be a fairly ordinary 12 months on the stocks. Subject to a positive TGA outcome I have to say that Rhythm's current circumstances as framed by Glenn Gilbert in this most recent presentation is an exception in the positive, notwithstanding the RHY share price being down a full third in the year to date. The impression given is that all the planning is now in place for commercial blast-off and all that needs to drop is a positive TGA decision. Overall I would rate Rhythm's achievements in 2022 a straight A, the only possible blemish being the time they took to apply to the TGA. I could say I blame the TGA for taking so long but in fairness they've had a shit three years or so and it would not surprise if they were dealing with burn-out of some of their key workers.